

REMARKS/ARGUMENTS


In response to the Office Action mailed on August 14, 2009, (Paper No. 20090811), the applicants elect the claims of Invention I (claim 1-33). Non-elected claims 34-39 have been canceled.

The Office Action also included a "Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosure." The Examiner noted that this application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR § 1.821 (a)(1) and (a)(2), but fails to comply with the requirements of 37 CFR §§ 1.821 through 1.825. More specifically, the Examiner noted that the Specification discloses nucleotide sequences on pages 14 and 19, but none of the sequences is identified by a SEQ ID NO.

The relevant paragraphs on pages 14 and 19 have been amended such that each of the sequences is identified by a SEQ ID NO. Therefore, the applicants respectfully submit that the specification, as amended, complies with 37 C.F.R. §§ 1.821 through 1.825.

Respectfully submitted,

April 12, 2010

  
\_\_\_\_\_  
John C. Pokotylo, Attorney  
Reg. No. 36,242  
Tel.: (732) 936-1400